

# Anavex Life Sciences

11:00 19 Oct 2018

## Anavex Life Sciences shares rise after FDA gives green light on Phase 2 trial

Anavex Life Sciences Corp (NASDAQ: AVXL) shares are on the rise following the US Food and Drug Administration's approval of its Investigational New Drug application for its Phase 2 trial of its drug Anavex2-73 for the treatment of Rett Syndrome.

Rett Syndrome is a rare, non-inherited neurological disorder that occurs mainly in girls and can lead to severe impairments, including losing the ability to speak, walk, eat and breathe.

**READ: Why Viking Therapeutics isn't waiting for a white knight**  
"The acceptance of this IND by the FDA is a significant milestone for Anavex2-73," stated CEO Christopher U. Missling in the company's press release.

"This is an important step toward achieving clinical data for the third indication for Anavex2-73 also incorporating genomic precision medicine biomarkers."

Shares of the New York-based biopharmaceutical company jumped nearly 14% to \$2.81 in Friday morning trading.

Anavex will proceed with a double-blind, randomized Phase 2 study using Anavex2-73 for the treatment of patients with Rett syndrome.

The company also has clinical development programs for the drug for the treatment of Alzheimer's disease and Parkinson's disease dementia.

Contact Lenore Fedow at [lenore@proactiveinvestors.com](mailto:lenore@proactiveinvestors.com)

Follow her on Twitter: [@LenoreMariee](https://twitter.com/LenoreMariee)

**Price:** US\$3.03

**Market Cap:** US\$153.72M

### 1 Year Share Price Graph



### Share Information

**Code:** AVXL

**Listing:** NASDAQ

**52 week High Low**  
**\$4.08 \$1.25**

**Sector:** Pharmaceuticals

**Website:** [www.anavex.com](http://www.anavex.com)

### Company Synopsis:

*Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer's disease, other CNS diseases and various types of cancer.*

### Author:

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.